- Home
- JHS vs KPTI Comparison
JHS vs KPTI Comparison
Compare JHS & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHS
- KPTI
- Stock Information
- Founded
- JHS 1973
- KPTI 2008
- Country
- JHS United States
- KPTI United States
- Employees
- JHS N/A
- KPTI N/A
- Industry
- JHS Finance Companies
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- JHS Finance
- KPTI Health Care
- Exchange
- JHS Nasdaq
- KPTI Nasdaq
- Market Cap
- JHS 134.3M
- KPTI 109.9M
- IPO Year
- JHS N/A
- KPTI 2013
- Fundamental
- Price
- JHS $11.39
- KPTI $0.81
- Analyst Decision
- JHS
- KPTI Strong Buy
- Analyst Count
- JHS 0
- KPTI 4
- Target Price
- JHS N/A
- KPTI $5.00
- AVG Volume (30 Days)
- JHS 32.8K
- KPTI 1.0M
- Earning Date
- JHS 01-01-0001
- KPTI 11-05-2024
- Dividend Yield
- JHS 3.96%
- KPTI N/A
- EPS Growth
- JHS N/A
- KPTI N/A
- EPS
- JHS 0.02
- KPTI N/A
- Revenue
- JHS N/A
- KPTI $148,442,000.00
- Revenue This Year
- JHS N/A
- KPTI $6.67
- Revenue Next Year
- JHS N/A
- KPTI $8.58
- P/E Ratio
- JHS $553.50
- KPTI N/A
- Revenue Growth
- JHS N/A
- KPTI 1.77
- 52 Week Low
- JHS $9.76
- KPTI $0.62
- 52 Week High
- JHS $11.25
- KPTI $1.95
- Technical
- Relative Strength Index (RSI)
- JHS 37.68
- KPTI 44.64
- Support Level
- JHS $11.38
- KPTI $0.86
- Resistance Level
- JHS $11.87
- KPTI $0.95
- Average True Range (ATR)
- JHS 0.13
- KPTI 0.08
- MACD
- JHS -0.01
- KPTI -0.01
- Stochastic Oscillator
- JHS 2.16
- KPTI 4.24
About JHS John Hancock Income Securities Trust
John Hancock Income Securities Trust is a United States-based closed-ended diversified management investment company. Its primary objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash & commercial paper.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.